Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial

Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective

“…(38) Emerging data also suggests that rosuvastatin may have an adverse effect on renal function, with signifi cant reductions in eGFR observed in patients with type 1 or 2 diabetes mellitus. (39) Evidence confi rms that the adverse effects of atorvastatin are similar across the dose range. (36,37) The Insulin Resistance Intervention after Stroke trial involving patients of South Asian origin with CHD also showed a dose-dependent reduction in LDL-C with atorvastatin and a comparable safety profi le in both arms of the study (i.e.…”

Rosuvastatin: winner in the statin wars, patients' health notwithstanding

“…18 Further concerns about rosuvastatin's renal effects were seen in an AstraZeneca funded randomized study comparing high dose rosuvastatin with atorvastatin in diabetic patients with progressive kidney disease. 19 Although rosuvastatin lowered plasma lipid concentrations to a greater extent than atorvastatin, the study reported that "atorvastatin seems to have more renoprotective effects." Urinary protein excretion was reduced during one year of treatment with atorvastatin 80 mg, with no significant changes in estimated glomerular filtration rate (eGFR).…”

Atorvastatin — 20 Years in the Struggle for Life

“…Снижение уровня СКФ, определенной на основании уровня циста-тина С, было статистически незначимым: -0,9 мл/ мин/1,73 м 2 ; р=0,69. По объединенным данным розу-вастатин в обоих дозах не влиял на уровень протеину-рии, однако значимо снижал уровень СКФ [109]. Благоприятный профиль безопасности аторваста-тина в отношении почек был продемонстрирован и ряде мета-анализов как в сравнении с плацебо [110], так и в сравнении с розувастатином [111,112].…”